EP3294761A4 - Compositions et méthodes de traitement et de prévention de l'infection pare. coli - Google Patents

Compositions et méthodes de traitement et de prévention de l'infection pare. coli Download PDF

Info

Publication number
EP3294761A4
EP3294761A4 EP16793641.8A EP16793641A EP3294761A4 EP 3294761 A4 EP3294761 A4 EP 3294761A4 EP 16793641 A EP16793641 A EP 16793641A EP 3294761 A4 EP3294761 A4 EP 3294761A4
Authority
EP
European Patent Office
Prior art keywords
pare
coli
infection
prevention
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16793641.8A
Other languages
German (de)
English (en)
Other versions
EP3294761A1 (fr
Inventor
Evgeni V. Sokurenko
Dagmara KISIELA
Wendy Evelyn THOMAS
Veronika L. TCHESNOKOVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Priority to EP20161093.8A priority Critical patent/EP3693379A1/fr
Publication of EP3294761A1 publication Critical patent/EP3294761A1/fr
Publication of EP3294761A4 publication Critical patent/EP3294761A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP16793641.8A 2015-05-13 2016-05-13 Compositions et méthodes de traitement et de prévention de l'infection pare. coli Withdrawn EP3294761A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP20161093.8A EP3693379A1 (fr) 2015-05-13 2016-05-13 Compositions et méthodes de traitement et de prévention de l'infection pare. coli

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562160852P 2015-05-13 2015-05-13
US201562208913P 2015-08-24 2015-08-24
PCT/US2016/032495 WO2016183501A1 (fr) 2015-05-13 2016-05-13 Compositions et méthodes de traitement et de prévention de l'infection par e. coli uropathogène

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP20161093.8A Division EP3693379A1 (fr) 2015-05-13 2016-05-13 Compositions et méthodes de traitement et de prévention de l'infection pare. coli

Publications (2)

Publication Number Publication Date
EP3294761A1 EP3294761A1 (fr) 2018-03-21
EP3294761A4 true EP3294761A4 (fr) 2019-04-03

Family

ID=57249555

Family Applications (2)

Application Number Title Priority Date Filing Date
EP20161093.8A Withdrawn EP3693379A1 (fr) 2015-05-13 2016-05-13 Compositions et méthodes de traitement et de prévention de l'infection pare. coli
EP16793641.8A Withdrawn EP3294761A4 (fr) 2015-05-13 2016-05-13 Compositions et méthodes de traitement et de prévention de l'infection pare. coli

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP20161093.8A Withdrawn EP3693379A1 (fr) 2015-05-13 2016-05-13 Compositions et méthodes de traitement et de prévention de l'infection pare. coli

Country Status (4)

Country Link
US (1) US10722580B2 (fr)
EP (2) EP3693379A1 (fr)
JP (1) JP2018515517A (fr)
WO (1) WO2016183501A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3693379A1 (fr) * 2015-05-13 2020-08-12 University of Washington Compositions et méthodes de traitement et de prévention de l'infection pare. coli
CA3079119A1 (fr) 2017-10-16 2019-04-25 Enterome Nouveaux outils pour evaluer l'efficacite therapeutique des bloqueurs fimh
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
MY209568A (en) 2020-01-16 2025-07-22 Janssen Pharmaceuticals Inc Fimh mutant, compositions therewith and use thereof
US12624095B2 (en) 2020-05-26 2026-05-12 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against pathological tau, and methods of detection thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
MX2023006320A (es) 2020-12-02 2023-06-14 Glaxosmithkline Biologicals Sa Cadena donante complementada fimh.
US12357681B2 (en) * 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
JP7532672B2 (ja) 2021-01-12 2024-08-13 ヤンセン ファーマシューティカルズ，インコーポレーテッド ＦｉｍＨ変異体、それを含む組成物、及びその使用
WO2022177724A1 (fr) * 2021-02-17 2022-08-25 University Of Rochester Procédés de traitement, de diagnostic et de prédiction du pronostic d'une sepsie
US20250304661A1 (en) * 2021-09-23 2025-10-02 Biomedit, Llc Vhh antibodies targeting fimh and methods of using the same
KR20240116841A (ko) 2021-12-17 2024-07-30 화이자 인코포레이티드 폴리뉴클레오티드 조성물 및 그의 용도
CA3248209A1 (fr) 2022-05-25 2023-11-30 CureVac SE Vaccin à base d’acide nucléique codant pour un polypeptide antigénique fimh d’escherichia coli
WO2026077990A1 (fr) * 2024-10-09 2026-04-16 Glaxosmithkline Intellectual Property Development Limited Nouvelle utilisation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087233A2 (fr) 2000-05-16 2001-11-22 New York University Anticorps anti-idiotypes diriges contre l'adhesine fimh d'escherichia coli uropathogene fimbrie du type i, compositions le contenant et son procede d'utilisation
US20030199071A1 (en) * 2000-12-08 2003-10-23 Solomon Langermann Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
US6780969B2 (en) * 2000-12-22 2004-08-24 United Biomedical, Inc. Synthetic peptide composition as immunogens for prevention of urinary tract infection
WO2007117339A2 (fr) * 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Composition immunogene a base de chimere adhesine-enterotoxine permettant de lutter contre l'escherichia coli enterotoxigene
US7888483B2 (en) * 2006-07-18 2011-02-15 Irm Llc Antagonists of protease activated receptor-1 (PAR1)
GB0803076D0 (en) * 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
AR078254A1 (es) * 2009-09-01 2011-10-26 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012047247A2 (fr) 2010-05-28 2012-04-12 Northwestern University Séparation de nanotubes de carbone monoparois par type électronique utilisant des copolymères séquencés
US9243057B2 (en) * 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
EP2867377B1 (fr) * 2012-07-02 2019-08-21 The Translational Genomics Research Institute Amorces, dosages et méthodes de détection d'un sous-type d'e. coli
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9504743B2 (en) * 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
AU2015220723C1 (en) * 2014-02-24 2018-04-05 Glaxosmithkline Biologicals Sa Novel polysaccharide and uses thereof
US9814769B2 (en) * 2014-09-30 2017-11-14 Qatar University Vaccines against pathogenic Escherichia coli and methods of using the same
EP3693379A1 (fr) * 2015-05-13 2020-08-12 University of Washington Compositions et méthodes de traitement et de prévention de l'infection pare. coli

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KISIELA DAGMARA I ET AL: "Inhibition and Reversal of Microbial Attachment by an Antibody with Parasteric Activity against the FimH Adhesin of Uropathogenic E. coli.", PLOS PATHOGENS, vol. 11, no. 5, E1004857, 14 May 2015 (2015-05-14), pages 1 - 22, XP055373031, ISSN: 1553-7374, DOI: 10.1371/journal.ppat.1004857 *
KISIELA DI, AVAGYAN H, FRIEND D, JALAN A, GUPTA S, INTERLANDI G, ET AL.: "Supplementary Information: Inhibition and Reversal of Microbial Attachment by an Antibody with Parasteric Activity against the FimH Adhesin of Uropathogenic E. coli", 14 May 2015 (2015-05-14), XP002786015, Retrieved from the Internet <URL:https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1004857#sec023> *
MARGARITA MARTINEZ-MEDINA ET AL: "Escherichia coli in chronic inflammatory bowel diseases: An update on adherent invasive Escherichia coli pathogenicity", WORLD JOURNAL OF GASTROINTESTINAL PATHOPHYSIOLOGY, vol. 5, no. 3, 1 January 2014 (2014-01-01), pages 213, XP055518717, ISSN: 2150-5330, DOI: 10.4291/wjgp.v5.i3.213 *
See also references of WO2016183501A1 *

Also Published As

Publication number Publication date
WO2016183501A1 (fr) 2016-11-17
US20180193457A1 (en) 2018-07-12
EP3294761A1 (fr) 2018-03-21
JP2018515517A (ja) 2018-06-14
US10722580B2 (en) 2020-07-28
EP3693379A1 (fr) 2020-08-12

Similar Documents

Publication Publication Date Title
EP3607072A4 (fr) Compositions et méthodes de traitement de la phénylcétonurie
EP3490582A4 (fr) Méthodes et compositions de traitement de maladie.
EP3370721A4 (fr) Traitement de l&#39;ostéoarthrite
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
EP3285776A4 (fr) Méthodes de traitement d&#39;infections bactériennes
GB201709530D0 (en) Prevention and treatment of microbial infections
EP3432891A4 (fr) Méthodes de traitement et de prévention d&#39;une infection à c. difficile
EP3423100A4 (fr) Compositions destinées à traiter l&#39;inflammation et méthodes de traitement associées
EP3512524A4 (fr) Méthodes et compositions de traitement d&#39;infections virales
EP3519058C0 (fr) Compositions et méthodes de traitement des cheveux
EP3641746A4 (fr) Méthodes et compositions pour le traitement d&#39;une infection microbienne
EP3317290A4 (fr) Compositions et méthodes de traitement d&#39;une infection virale
EP3347032A4 (fr) Traitement de l&#39;ascite
EP3801478A4 (fr) Méthodes et compositions pour la prévention ou le traitement de la calciphylaxie
EP3386507A4 (fr) Méthodes et compositions de traitement des ulcères gastriques
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l&#39;amyloïdose
EP3599983A4 (fr) Endoscopes et méthodes de traitement
EP3493823C0 (fr) Composé à base de postbiotique pour le traitement de l&#39;inflammation oculaire
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
EP3373922A4 (fr) Compositions et méthodes pour le traitement de l&#39;homocystinurie
EP3292872C0 (fr) Composition pour le traitement ou la prévention de maladies infectieuses inflammatoires ou composition pour l&#39;amélioration de l&#39;immunité comprenant de la tryptophanyl-arnt synthétase en tant que principe actif
EA201890188A1 (ru) Новый бициклический липолантипептид, его получение и применение в качестве противомикробного средства
EP3302458A4 (fr) Méthodes de prévention et de traitement de l&#39;auto-immunité
EP3518951A4 (fr) Compositions et méthodes pour le traitement d&#39;affections orthopédiques
SG11201809811VA (en) Compositions and methods for treatment of inflammation or infection of the eye

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/12 20060101ALI20181112BHEP

Ipc: A61P 1/04 20060101ALI20181112BHEP

Ipc: A61P 31/04 20060101ALI20181112BHEP

Ipc: C07K 14/245 20060101AFI20181112BHEP

Ipc: A61K 39/395 20060101ALI20181112BHEP

Ipc: A61P 13/10 20060101ALI20181112BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/12 20060101ALI20181119BHEP

Ipc: A61P 31/04 20060101ALI20181119BHEP

Ipc: A61P 1/04 20060101ALI20181119BHEP

Ipc: A61K 39/395 20060101ALI20181119BHEP

Ipc: A61P 13/10 20060101ALI20181119BHEP

Ipc: C07K 14/245 20060101AFI20181119BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20190301

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/245 20060101AFI20190225BHEP

Ipc: C07K 16/12 20060101ALI20190225BHEP

Ipc: A61K 39/395 20060101ALI20190225BHEP

Ipc: A61P 31/04 20060101ALI20190225BHEP

Ipc: A61P 1/04 20060101ALI20190225BHEP

Ipc: A61P 13/10 20060101ALI20190225BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20201201